Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Chemotherapy-induced immune suppression has mainly been studied in patients with advanced cancer, but the influence of chemotherapy on the immune system in early stage cancer patients has so far not been studied systematically. The aim of the present study was to monitor the immune system during anthracycline- and taxane-based adjuvant chemotherapy in early stage breast cancer patients, to assess the impact of circulating tumor cells on selected immune parameters and to reveal putative angiogenic effects of circulating endothelial cells. Methods: Peripheral blood samples from 20 early stage breast cancer patients were analyzed using a flow cytometric multi-color of antibodies to enumerate lymphocyte and dendritic cell subsets, as well as endothelial and tumor cells. An enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of various serological factors. Results: During chemotherapy, all immunological parameters and angiogenesis surrogate biomarkers showed significant decreases. The numbers of circulating tumor cells showed significant inverse correlations with the numbers of T helper cells, a lymphocyte subset directly related to effective anti-tumor responses. Reduced T helper cell numbers may contribute to systemic immunosuppression and, as such, the activation of dormant tumor cells. Conclusions: From our results we conclude that adjuvant chemotherapy suppresses immune function in early stage breast cancer patients. In addition, we conclude that the presence of circulating tumor cells, defined as pan-cytokeratin+, CD326+, CD45 cells, may serve as an important indicator of a patient’s immune status. Further investigations are needed to firmly define circulating tumor cells as a predictor for the success of breast cancer adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalCellular Oncology
DOIs
Publication statusAccepted/In press - Jan 14 2016

Fingerprint

Adjuvant Chemotherapy
Tumor Biomarkers
Circulating Neoplastic Cells
Breast Neoplasms
Neoplasms
Drug Therapy
Immune System
Endothelial Cells
Anthracyclines
Lymphocyte Subsets
Keratins
Helper-Inducer T-Lymphocytes
Immunosuppression
Dendritic Cells
Color
Cell Count
Biomarkers
Enzyme-Linked Immunosorbent Assay
Lymphocytes
Antibodies

Keywords

  • Adjuvant breast cancer chemotherapy
  • Cytokine
  • Dendritic cells
  • Endothelial cells
  • Lymphocyte subsets
  • Tumor cells

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology

Cite this

@article{db9885fe0d654a77bf75c989a6d77cdd,
title = "Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy",
abstract = "Background: Chemotherapy-induced immune suppression has mainly been studied in patients with advanced cancer, but the influence of chemotherapy on the immune system in early stage cancer patients has so far not been studied systematically. The aim of the present study was to monitor the immune system during anthracycline- and taxane-based adjuvant chemotherapy in early stage breast cancer patients, to assess the impact of circulating tumor cells on selected immune parameters and to reveal putative angiogenic effects of circulating endothelial cells. Methods: Peripheral blood samples from 20 early stage breast cancer patients were analyzed using a flow cytometric multi-color of antibodies to enumerate lymphocyte and dendritic cell subsets, as well as endothelial and tumor cells. An enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of various serological factors. Results: During chemotherapy, all immunological parameters and angiogenesis surrogate biomarkers showed significant decreases. The numbers of circulating tumor cells showed significant inverse correlations with the numbers of T helper cells, a lymphocyte subset directly related to effective anti-tumor responses. Reduced T helper cell numbers may contribute to systemic immunosuppression and, as such, the activation of dormant tumor cells. Conclusions: From our results we conclude that adjuvant chemotherapy suppresses immune function in early stage breast cancer patients. In addition, we conclude that the presence of circulating tumor cells, defined as pan-cytokeratin+, CD326+, CD45− cells, may serve as an important indicator of a patient’s immune status. Further investigations are needed to firmly define circulating tumor cells as a predictor for the success of breast cancer adjuvant chemotherapy.",
keywords = "Adjuvant breast cancer chemotherapy, Cytokine, Dendritic cells, Endothelial cells, Lymphocyte subsets, Tumor cells",
author = "B. Rovati and S. Mariucci and S. Delfanti and D. Grasso and C. Tinelli and C. Torre and {de Amici}, M. and P. Pedrazzoli",
year = "2016",
month = "1",
day = "14",
doi = "10.1007/s13402-015-0264-2",
language = "English",
pages = "1--18",
journal = "Cellular oncology (Dordrecht)",
issn = "2211-3428",
publisher = "IOS Press",

}

TY - JOUR

T1 - Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy

AU - Rovati, B.

AU - Mariucci, S.

AU - Delfanti, S.

AU - Grasso, D.

AU - Tinelli, C.

AU - Torre, C.

AU - de Amici, M.

AU - Pedrazzoli, P.

PY - 2016/1/14

Y1 - 2016/1/14

N2 - Background: Chemotherapy-induced immune suppression has mainly been studied in patients with advanced cancer, but the influence of chemotherapy on the immune system in early stage cancer patients has so far not been studied systematically. The aim of the present study was to monitor the immune system during anthracycline- and taxane-based adjuvant chemotherapy in early stage breast cancer patients, to assess the impact of circulating tumor cells on selected immune parameters and to reveal putative angiogenic effects of circulating endothelial cells. Methods: Peripheral blood samples from 20 early stage breast cancer patients were analyzed using a flow cytometric multi-color of antibodies to enumerate lymphocyte and dendritic cell subsets, as well as endothelial and tumor cells. An enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of various serological factors. Results: During chemotherapy, all immunological parameters and angiogenesis surrogate biomarkers showed significant decreases. The numbers of circulating tumor cells showed significant inverse correlations with the numbers of T helper cells, a lymphocyte subset directly related to effective anti-tumor responses. Reduced T helper cell numbers may contribute to systemic immunosuppression and, as such, the activation of dormant tumor cells. Conclusions: From our results we conclude that adjuvant chemotherapy suppresses immune function in early stage breast cancer patients. In addition, we conclude that the presence of circulating tumor cells, defined as pan-cytokeratin+, CD326+, CD45− cells, may serve as an important indicator of a patient’s immune status. Further investigations are needed to firmly define circulating tumor cells as a predictor for the success of breast cancer adjuvant chemotherapy.

AB - Background: Chemotherapy-induced immune suppression has mainly been studied in patients with advanced cancer, but the influence of chemotherapy on the immune system in early stage cancer patients has so far not been studied systematically. The aim of the present study was to monitor the immune system during anthracycline- and taxane-based adjuvant chemotherapy in early stage breast cancer patients, to assess the impact of circulating tumor cells on selected immune parameters and to reveal putative angiogenic effects of circulating endothelial cells. Methods: Peripheral blood samples from 20 early stage breast cancer patients were analyzed using a flow cytometric multi-color of antibodies to enumerate lymphocyte and dendritic cell subsets, as well as endothelial and tumor cells. An enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of various serological factors. Results: During chemotherapy, all immunological parameters and angiogenesis surrogate biomarkers showed significant decreases. The numbers of circulating tumor cells showed significant inverse correlations with the numbers of T helper cells, a lymphocyte subset directly related to effective anti-tumor responses. Reduced T helper cell numbers may contribute to systemic immunosuppression and, as such, the activation of dormant tumor cells. Conclusions: From our results we conclude that adjuvant chemotherapy suppresses immune function in early stage breast cancer patients. In addition, we conclude that the presence of circulating tumor cells, defined as pan-cytokeratin+, CD326+, CD45− cells, may serve as an important indicator of a patient’s immune status. Further investigations are needed to firmly define circulating tumor cells as a predictor for the success of breast cancer adjuvant chemotherapy.

KW - Adjuvant breast cancer chemotherapy

KW - Cytokine

KW - Dendritic cells

KW - Endothelial cells

KW - Lymphocyte subsets

KW - Tumor cells

UR - http://www.scopus.com/inward/record.url?scp=84954325741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954325741&partnerID=8YFLogxK

U2 - 10.1007/s13402-015-0264-2

DO - 10.1007/s13402-015-0264-2

M3 - Article

AN - SCOPUS:84954325741

SP - 1

EP - 18

JO - Cellular oncology (Dordrecht)

JF - Cellular oncology (Dordrecht)

SN - 2211-3428

ER -